Isobel Fisher - November 11, 2024 AI designer enzymes During the announcement of the first survey of the entire human genome by the Human Genome Project, ...
Joseph Newcombe - September 18, 2024 Professor David Nutt’s new psychedelic mission The expert on drugs is researching the potential to treat mental health disorders with ...
Robert Andrews - August 20, 2024 Antibody-drug conjugates: the new frontier of cancer treatments Antibody-drug conjugates (ADCs) are big business. Big pharma is moving in, snapping up companies or ...
Adam Gregory - July 15, 2024 Mewburn Ellis is proud to have worked on 26 of the 100 top-selling pharmaceuticals of 2023 Mewburn Ellis is proud to work with some of the world’s most globally significant pharmaceuticals, ...
Joseph Newcombe - June 24, 2024 FDA decision on MDMA therapy hangs in the balance Recent positive data from a phase III clinical trial of MDMA assisted psychotherapy for the ...
Camille Terfve - April 26, 2024 The brilliant dawn of AI drug discovery Computer simulations are solving challenges previously thought uncrackable.
Rebecca Brooks - February 29, 2024 Updates to the Guidelines for Examination at the EPO The Guidelines for Examination at the EPO (which will be referred to as “the Guidelines” in this ...
Katherine Green - February 2, 2024 Most opposed patents of 2023 Multiple sclerosis therapies are the subject of two of the most opposed patents of 2023. Novartis’ ...
Emily Sullivan - January 9, 2024 Pharma trade marks: 2023 EU case law round up As we enter 2024, we reflect on the lessons we have learned in 2023. The trade mark landscape has ...
Emily Lythell - January 5, 2024 Antibiotic with novel mechanism offers new hope for treating resistant infections This week saw the publication of a potential new class of antibiotics and their mechanism ...
Amelia Jones - December 19, 2023 Synthetic probiotics: bacteria that link the gut to the brain Optimising pharmacokinetics of a drug is a vital stage of the development process. Pharmacokinetics ...
Joseph Newcombe - December 12, 2023 New highs for psychedelics in the clinic Psychedelic compounds have long been experimented with for their mind-altering properties, but in ...
Jamie Emerick - November 15, 2023 EU General Court provides guidance on consumer perception in the pharmaceutical industry Earlier this year, in March 2023, the European Union’s General Court provided some useful ...
Katherine Green - November 13, 2023 Most opposed patents of 2022 As with CRISPR, patents directed to Nobel Prize-winning technologies are viewed as extremely ...
Jacqueline Murphy - November 8, 2023 Validating European patents outside Europe - the Validation State system We are pleased to launch our latest report Validating European patents outside Europe - the ...
Nick Sutcliffe - October 3, 2023 Covid autumn booster vaccine 2023: the switch to mono-valent vaccines Autumn 2023 sees another round of COVID-19 booster jabs across the UK for vulnerable people.
Amelia Jones - September 5, 2023 A leap forward in slowing down Alzheimer’s This summer has seen a major leap forward in slowing the rate of progression of Alzheimer’s disease.
Joseph Newcombe - September 5, 2023 Meet The Team: Joseph Newcombe, Associate and Patent Attorney, Sustainable Pharma Commentator As part of our 'meet the team' series, we talk to Joseph Newcombe about being involved in the ...
Rebecca Anderson-Smith - September 1, 2023 Building an international Customs strategy for your pharma brand Counterfeit pharmaceuticals are a global problem and pose a significant threat to consumers and ...
Emily Sullivan - August 31, 2023 Understanding parallel import of pharmaceuticals in the EU – a quick guide to repackaging and relabelling of parallel imports for brand owners Parallel importing, the practice where third parties import branded goods already put on sale by ...
Karolina Fryzlewicz - August 25, 2023 Strategic Pharmaceutical Branding: when should you apply to register a trade mark if still undergoing clinical trials? Tying trade mark considerations into your drug development strategy can be a rather challenging ...
Rebecca Anderson-Smith - August 4, 2023 Court of Appeal confirms filing a trade mark cancellation action does not ‘stop the clock’ on acquiescence In our “Pharma trade marks: 2022 case law round up” (written towards the end of November 2022) we ...
Edward Couchman - August 1, 2023 US Supreme Court Upholds Tightening of Patent Enablement Standard In an eagerly awaited judgement, the US Supreme Court has affirmed the standard applied by the ...
David Brooks - July 19, 2023 Mewburn Ellis is proud to work on 18 of the 50 top-selling pharmaceuticals of 2022 Last year we reported the unprecedented growth of the innovative pharmaceuticals industry in 2021 ...
Joseph Newcombe - April 26, 2023 Joe Newcombe in PharmaTimes — new order In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s ...
Joe McAlary - March 28, 2023 Can parallel importers apply registered trade marks to previously unbranded products? Towards the back end of last year, the Court of Justice of the European Union (CJEU) gave a series ...
Robert Watson - March 2, 2023 Julie Carlisle and Robert Watson in PharmaTimes — everything I own? Featured in PharmaTimes, Julie Carlisle and Robert Watson dig deep into the maelstrom of ...
Joseph Newcombe - March 1, 2023 Joe Newcombe in PharmaTimes — circle of life In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s ...
Christopher Casley - February 9, 2023 AI and Tech innovation stands out in a slow year for pharma deals Last year saw a drop in the number and value of deals performed in the biotech and pharma sector ...
Karolina Fryzlewicz - February 6, 2023 Curing pharmaceutical trade mark deficiencies: EU guidance on “food supplements” and “pharmaceutical products” in Hasco TM v EUIPO Making genuine use of trade marks after registration is of fundamental importance to avoid the ...
Nick Sutcliffe - December 20, 2022 mRNA cancer vaccine shows efficacy in clinical trial Moderna and Merck announced in a mid-December 2022 press release that its mRNA cancer vaccine ...
Joseph Newcombe - December 8, 2022 Joe Newcombe in PharmaTimes — Reality checked In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks at how COP27 ...
Rebecca Anderson-Smith - December 2, 2022 Pharma trade marks: 2022 case law round up As we enter December, and the year draws to a close, many trade mark practitioners and brand owners ...
Joe McAlary - December 2, 2022 Parallel imports of repackaged pharmaceutical products - clarification from recent CJEU rulings Recent case law of the Court of Justice of the European Union (CJEU) has clarified how the ...
Joseph Newcombe - November 25, 2022 Joe Newcombe in PharmaTimes — We are the robots In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks his experience at ...
Jacqueline Murphy - November 21, 2022 Pharma Trade Marks: Exhaustion and Parallel Trade in the UK - Special Report 2022 We are excited to announce the release of our latest special report Pharma Trade Marks: Exhaustion ...
Thomas Wolter - November 21, 2022 Plausibility and Inventive Step at the EPO - Watch G2/21 live on Thursday 24 November On Thursday 24 November 2022, the Enlarged Board of Appeal (EBA) will hear the parties in case ...
Julie Carlisle - November 16, 2022 European validation strategies for pharmaceutical patents – an update In January 2021, we published our Special Report on EP validation strategies for pharmaceutical ...
Matthew Barton - November 1, 2022 Vets: who’s taking care of the animal caregivers? Our pets are members of the family, and we would do everything we can to make sure they stay fit ...
Fynn McLennan - October 17, 2022 Picky and potent: bioorthogonal chemistry in therapy There exist chemical moieties that are essentially invisible to the machinery in the mammalian ...
Maria Hall - October 14, 2022 Robert Watson elected President of FICPI’s Study and Work Committee Partner Robert Watson was elected President of FICPI’s Study and Work Committee (Commission d'Etude ...
Joseph Newcombe - October 11, 2022 Joe Newcombe in PharmaTimes — biohazard In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s ...
Joseph Newcombe - August 1, 2022 Joe Newcombe in PharmaTimes — chemical reaction In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s ...
Katherine Green - July 28, 2022 Most opposed patents of 2021 When we reviewed our list of the most opposed European patents of 2021, we found that the patent at ...
Adam Gregory - July 22, 2022 Mewburn Ellis is proud to work on 19 of the 50 top-selling pharmaceuticals of 2021 2021 was a year of unprecedented success for the biotech and pharmaceutical industries, with the ...
Fynn McLennan - July 5, 2022 Bacteria: a surface level understanding Surfaces pose a unique challenge in the on-going war against pathogenic bacteria. Bacteria may ...
Thomas Wolter - June 27, 2022 EPO presses pause on proceedings that depend on the plausibility referral to the EBA Despite not having any express legislative basis in the European Patent Convention, plausibility ...
Julie Carlisle - June 22, 2022 The surprising world of canine oncology Dog cancer specialist Dr Clare Knottenbelt reveals the insights derived from studying and treating ...
Joseph Newcombe - May 2, 2022 Joe Newcombe in PharmaTimes — green party In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s ...
Thomas Wolter - April 27, 2022 Plausibility strikes again – BMS blockbuster apixaban patent found invalid by UK High Court In a recent judgment the UK High Court of Justice revoked European Patent (UK) 1 427 415 B1 and a ...
Tanis Keirstead - April 14, 2022 Horizons in vaccine production The scramble for a coronavirus vaccine over the last two years has demonstrated how important ...
Tanis Keirstead - April 4, 2022 A much-needed boost: the future of coronavirus vaccines Just over two years after our first blog on Covid-19, it appears that the disease is here to stay. ...
Joseph Newcombe - April 1, 2022 Joe Newcombe in PharmaTimes — breath of fresh air In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s ...
Jacqueline Murphy - March 23, 2022 Non-traditional pharmaceutical trade marks - new special report We are excited to announce the launch of our latest special report Non-traditional pharmaceutical ...
Joseph Newcombe - March 1, 2022 Joe Newcombe in PharmaTimes — a force of nature In his regular PharmaTimes feature, sustainability columnist Joe Newcombe looks out to pharma’s ...
Joseph Newcombe - November 19, 2021 A cleaner, greener future for pharma The pharma industry is centred on the mission of providing life-saving medicines for healthcare. In ...
Camille Terfve - November 12, 2021 Digital therapeutics: the rise of digital health technologies during the Covid-19 pandemic There is no denying that the Covid-19 pandemic has reshaped many aspects of our lives. Those lucky ...
Andrew Williams - October 5, 2021 Change and Opportunity: SPCs in the post-Brexit era Supplementary Protection Certificates (SPCs) are incredibly important IP rights that help ...
Sam Bailey - September 8, 2021 Could the pause in SPC-related referrals to the CJEU be permanent? As part of our Thought Leaders series, Mewburn Ellis Partner Sam Bailey considers whether a pause ...
Andrew Pitts - August 10, 2021 A new referral to the EPO’s Enlarged Board of Appeal is plausible Despite not having any express legislative basis in the European Patent Convention, plausibility ...
Daniel Yin - July 28, 2021 Senolytics are knock, knock, knocking on ageing’s door In 1974, Bob Dylan asked that we stay forever young. Today, exciting developments in the longevity ...
Fay Allen - July 28, 2021 Is metformin the key to anti-aging? By 2050, it is estimated that one quarter of the global population will be over 60 years old. That ...
Niles Beadman - July 20, 2021 Printed pills: a new dimension for medicine Three dimensional (3D) printing is the latest buzzword ricocheting through high-tech industries and ...
Rebecca Anderson-Smith - July 6, 2021 Non-traditional pharma trade marks: position marks In this final blog in our non-traditional pharma trade mark series, we will be examining position ...
Jacqueline Murphy - June 23, 2021 Pharma and Life Sciences Patent Extensions in Europe Our Special Report Pharma and Life Sciences Patent Extensions in Europe examines five years of data ...
Sarah Kostiuk-Smith - June 21, 2021 Podcast with Sarah Kostiuk-Smith: Validation strategies for pharmaceutical patents in Europe Sarah Kostiuk-Smith, Partner and Patent Attorney at Mewburn Ellis (UPDATE 30 SEPTEMBER 2022: Sarah ...
Jo Cripps - June 8, 2021 Need to Know: why your virome holds enormous value Our bodies play host to a complex network of viruses, many of which remain unclassified. Matt ...
Samuel Hart - June 3, 2021 Healthy eating means more than just a balanced diet: future foods and fighting the risk of infection Human health is inextricably linked to food – not least because eating a healthy diet is known to ...
Genevieve Pugh - June 1, 2021 Delivering drugs with DNA We explore the emerging field of DNA and RNA nanotechnology, its benefits and highlight a few ways ...
Rebecca Anderson-Smith - May 27, 2021 Non-traditional pharma trade marks: sound, motion and multimedia marks Following on from our previous blog posts examining the role of shape marks and colour marks in the ...
Emma Kennaugh-Gallacher - May 21, 2021 Patent Settlement Agreements with a “Pay for Delay” element – restrictive ‘by object’? Almost two decades ago the European Commission (EC) launched a significant and far-reaching ...
Joseph Newcombe - April 26, 2021 COVID-19 win for AI pharma farmers The vaccine roll-out is in action all over the world. Nevertheless, given the propensity of ...
Rebecca Anderson-Smith - April 21, 2021 Non-traditional pharma trade marks: colours Our previous blog post, Non-traditional pharma trade marks: shapes, explored the relevance of shape ...
Adam Gregory - April 19, 2021 Jim Mellon: the reluctant gradualist taking on ageing Forward editor Caitlin Mackesy Davies learns how we might all be able to live long and prosper from ...
Sarah Harvey - March 23, 2021 EPO 2020 Patent Index - key trends The European Patent Office (EPO) recently published its 2020 Patent Index which provides a ...
Rebecca Anderson-Smith - March 23, 2021 Non-traditional pharma trade marks: shapes In our previous blog post 'Naming pharmaceuticals: considerations for choosing, clearing and ...
Rebecca Anderson-Smith - March 22, 2021 Pharma brands: what's in a name? Pinning down a new drug name that will both catch attention and clear regulatory hurdles requires ...
Eleanor Maciver - March 12, 2021 Selection inventions before the EPO Chemical inventions are subject to the same criteria as all inventions at the European Patent ...
Robert Watson - February 5, 2021 Out of Oz: the remarkable life and times of AMP945 Bringing a new cancer treatment to the public can be a complex process, as Alex Eliseev finds out.
Jacqueline Murphy - February 4, 2021 New Special Report: Validation Strategies for Pharmaceutical Patents in Europe We are excited to announce the launch of our new Validation Strategies for Pharmaceutical Patents ...
Niles Beadman - January 26, 2021 Antimicrobial resistance: experience vs. experts Oxford University have announced the launch of a world-leading institute to fight antimicrobial ...
Eliot Ward - December 21, 2020 Will the COVID-19 vaccines induce more robust immunity than infection with SARS-Cov-2 itself? Respiratory viruses such as coronaviruses are notorious for evading the immune system[1] and, in ...
Nick Sutcliffe - November 25, 2020 AstraZeneca/Oxford University vaccine shows efficacy against SARS-CoV-2 AstraZeneca/Oxford University have announced that their SARS-CoV-2 candidate vaccine AZD1222 showed ...
Nick Sutcliffe - November 16, 2020 And then there were two – Moderna SARS-CoV-2 vaccine shows efficacy Moderna have announced that their SARS-CoV-2 vaccine candidate mRNA1273 showed efficacy in a first ...
Nick Sutcliffe - November 13, 2020 Pfizer and BioNTech vaccine provides protection against SARS-CoV-2 Pfizer/BioNTech have now released more data from the Phase 3 clinical trial of the BNT162b2 ...
Joseph Newcombe - October 29, 2020 Personalising medicine based on gut reaction No, we are not talking about jumping to conclusions, but the reactions carried out by the gut ...
Rebecca Anderson-Smith - October 28, 2020 Naming pharmaceuticals: considerations for choosing, clearing and registering pharmaceutical brand names There are many different types of names you might see associated with a pharmaceutical product.
Adam Gregory - October 27, 2020 Hummingbird Bioscience to start clinical trials for SARS-CoV-2-targeted antibody, HMBD-115 Our client, Hummingbird Bioscience, has received regulatory authorisation to initiate clinical ...
Melodie Richardson - September 4, 2020 Combatting COVID-19: does Vitamin D have a role to play? Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), better known as COVID-19 or simply ...
Jane Liu - September 2, 2020 The emergence of liquid biopsies as companion diagnostics The development of liquid biopsies The term liquid biopsy refers to the use of different body ...
Joseph Newcombe - September 2, 2020 Polymorphism: crystal clear or murky water Movers and shapeshifters in the world of solid state chemistry Have you ever left a bar of ...
Eleanor Maciver - August 28, 2020 Antimicrobial resistance – a global response to a global threat The discovery and development of antimicrobial agents and particularly antibiotics is recognised as ...
James Leach - August 10, 2020 Antimicrobial resistance: moving towards a targeted approach Spectromics is working to put our existing arsenal of antibiotics to best use in the fight against ...
Julie Carlisle - July 5, 2020 Medicine's most wanted Will the world's most dangerous microbes soon meet their match? Forward finds out what's in the ...
Helen Bower - June 19, 2020 Financial Times: Europe's Leading Patent Law Firms 2020 We are delighted to once again be recognised in the Financial Times’ annual report on Europe’s ...
Joseph Newcombe - June 12, 2020 Hot Chemistry – Shining a light on disease with radiopharmaceuticals Back in 1979 The Buggles sang “video killed the radio star”. However, the radio(pharmaceutical) ...
Julie Carlisle - June 1, 2020 Is faster drug development likely to become the “new normal?” As part of our Thought Leaders series, Sarah Kostiuk-Smith explores whether faster drug development ...
Richard Clegg - May 14, 2020 Singapore's biotech breakthrough From the far east to the east coast of America, the world is taking note of a new energy surging ...
Rhiannon Wescott - May 1, 2020 Can a functionally defined patent claim ‘protect’ my medicinal product? From a patent perspective this may seem like a strange question with an obvious answer; “of ...
Robert Andrews - April 30, 2020 BerGenBio’s bemcentinib selected for fast track as potential treatment for coronavirus (COVID-19) In the fight against the coronavirus pandemic, bemcentinib produced by BerGenBio has been selected ...
Julie Carlisle - April 20, 2020 Has a cure for coronavirus (COVID-19) already been made? Faced with the biggest global pandemic in most of our lifetimes, all around the world research ...
Tanis Keirstead - March 24, 2020 Coronavirus (COVID-19): a case study in emerging disease UPDATE 14 APRIL 2022: In his blog Horizons in vaccine production, we explore pressing need to ...
Lucy White - March 23, 2020 Vaccine platform technologies to combat emerging infectious diseases The SARS-CoV-2 outbreak is now a global pandemic. In a previous post, we discussed the need to act ...
Rebecca Anderson-Smith - March 19, 2020 Parallel imports of pharmaceuticals – A UK trade mark perspective The UK parallel import licensing scheme lets a medicine authorised in another EU Member State be ...
Anna Mudge - February 21, 2020 2020 BioInfect Conference - tackling antimicrobial resistance Antimicrobial resistance (AMR) poses a global threat. No new classes of antibiotics have been ...
Alison Fugard - February 21, 2020 Darobactin – worming our way out of antibiotic resistance Recently, we have been exploring antimicrobial resistance and the possible solutions to this ...
Anna Mudge - February 19, 2020 What makes Massachusetts small but mighty? Deirdre Sanders, president of the Boston Patent Law Association and a principle at Hamilton Brook ...
Thomas Driver - February 6, 2020 Genetic engineering and synthetic biology – making cannabis production greener The therapeutic benefits of medicinal cannabis have been liberally splashed across newspaper ...
Jane Liu - January 23, 2020 A promising target for new antibiotics In previous blogs we have discussed the global threat of antimicrobial resistance and some of the ...
Callum McGuinn - November 12, 2019 Using IP to secure opportunities in the budding medical cannabis sector The opportunities for innovation in medical cannabis dovetails with the opportunity to obtain ...
Andrew Pitts - October 16, 2019 Infecting the infection to tackle the rise in chemical antibiotic resistance In previous blogs we have highlighted how certain families of bacteria are highly resistant to ...
Julie Carlisle - September 27, 2019 AMR - a global threat A hot topic on everyone’s lips at the moment is Climate Change and its predicted impact on our way ...
Callum McGuinn - September 26, 2019 Budding opportunities for pharma With shifting attitudes surrounding cannabis-based drugs, it is essential to explore the array of ...
Joseph Newcombe - September 25, 2019 From data to drugs - a brief introduction to AI in drug discovery The road to an approved drug is well known to be an arduous journey. Recent estimates put the cost ...
Callum McGuinn - September 17, 2019 Cannabis: on to greener pastures? Callum McGuinn, explores the history of social attitudes towards cannabis and asks what the future ...
Callum McGuinn - June 18, 2019 Medicinal cannabis: recent changes and future innovations Government policy on the prescription of cannabis-derived medicines has undergone some interesting ...
Julie Carlisle - May 20, 2019 Protecting the ‘Trojan horse’ drug key to keeping a struggling field viable An Expert View column originally published in The Pharma Letter. Read the original article here. ...
Julie Carlisle - March 28, 2019 Dosage regimen patents: bruised but not beaten Ruling on the big pharma Actavis v ICOS case, the UK Supreme Court has found ICOS’s Cialis patent ...
Emily Hayes - March 25, 2019 Playing for time: strategies that can help extend a drug's patent life In our new magazine Forward, we interview C Hunter Baker of Wolf, Greenfield & Sacks PC. Hunter ...
Sean Jauss - January 14, 2019 Eight key themes from the J.P. Morgan Healthcare Conference I’ve spent the last few days talking with biotech entrepreneurs, VC fund managers and lawyers ...
Richard Clegg - December 10, 2018 Clovis Oncology success in European Opposition Proceedings related to Rubraca® Clovis Oncology has announced that the European Patent Office (EPO) last week upheld claims of ...
Anna Mudge - December 2, 2018 The importance of Innovation Hubs in the UK's North West Region Life science ‘start-ups’, ‘spin-outs’ and SMEs are some of the most innovative businesses and are ...
Nick Sutcliffe - November 14, 2018 Supreme Court decision signals bad news for patent holders The UK Supreme Court issued its decision today on the Warner Lambert vs Generics (UK) Ltd t/a ...
Matthew Smith - October 29, 2018 Development in the war on superbugs The spread of antibiotic-resistant infections is one of the most serious threats in modern ...
Callum Anderson - August 1, 2017 UK Supreme Court Establishes Doctrine of Equivalents in Actavis v Lilly In many jurisdictions a product or process may be held to infringe even though it falls outside the ...
